Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study.

Bridel, Claire; Beauverd, Yan; Samii, Kaveh; Lalive, Patrice H

Bridel, Claire; Beauverd, Yan; Samii, Kaveh; Lalive, Patrice H.

Afiliação

Bridel C; Department of Clinical Neurosciences (C.B., P.H.L.), Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis; Department of Hematology (Y.B., K.S.); and Department of Genetics and Laboratory Medicine (P.H.L.), Laboratory Medicine Service, University Hospital of Geneva, Switzerland.
Beauverd Y; Department of Clinical Neurosciences (C.B., P.H.L.), Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis; Department of Hematology (Y.B., K.S.); and Department of Genetics and Laboratory Medicine (P.H.L.), Laboratory Medicine Service, University Hospital of Geneva, Switzerland.
Samii K; Department of Clinical Neurosciences (C.B., P.H.L.), Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis; Department of Hematology (Y.B., K.S.); and Department of Genetics and Laboratory Medicine (P.H.L.), Laboratory Medicine Service, University Hospital of Geneva, Switzerland.
Lalive PH; Department of Clinical Neurosciences (C.B., P.H.L.), Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis; Department of Hematology (Y.B., K.S.); and Department of Genetics and Laboratory Medicine (P.H.L.), Laboratory Medicine Service, University Hospital of Geneva, Switzerland.

Neurol Neuroimmunol Neuroinflamm ; 2(4): e123, 2015 Aug.

Article em En | MEDLINE | ID: mdl-26140281

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Neurol Neuroimmunol Neuroinflamm Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google